Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
The Company also completed a $1.5 million convertible note bridge financing.
- The Company also completed a $1.5 million convertible note bridge financing.
- The acquired Varian asset platform is a novel, potential high-potency, specific, aPKCi with possible broad use in oncology as well as certain rare malignant diseases.
- “Completion of the Varian asset acquisition and the bridge financing represents a potentially transformative next step for Windtree.
- Additional details are available by reading the Company’s Current Report on Form 8-K relating to the Varian asset acquisition and senior convertible note bridge financing, which was filed with the Securities and Exchange Commission on April 8, 2024.